Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinocare Pays $200 Million for Second US Diabetes Monitoring Device Company

publication date: May 2, 2016
Sinocare of Shangsha will pay up to $200 million to acquire PTS Diagnostics of Indianapolis, a company that makes point-of-care blood testing devices. PTS make devices that test glucose, lipid or nicotine levels in the blood. The PTS transaction is Sinocare's second purchase of a US company in six months. In November 2015, Sinocare paid $273 million for Nipro Diagnostics of Florida, the US division of Japan's Nipro, which also makes glucose monitoring products. In China, Sinocare is in the biosensors business, including diabetes monitoring devices. More details. . . .

Stock Symbol: (SHZ: 300298)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital